Biosign Signs European Distribution Agreement

Toronto, July 2, 2010 (ots/PRNewswire) - Biosign Technologies Inc.
(CNSX: BIO) today announced the signing of an exclusive Master
Distribution Agreement with Swiss-based DynamiCARE AG to distribute
the Biosign products in Switzerland, Germany, France, and Austria,
with an option to expand distribution throughout Europe. Under the
terms of the agreement, DynamiCARE will pay an initial fee of CDN
$2.5 million, with a commitment to achieve sales in excess of CDN
$100 million in 2011.

The initial fee is payable upon UFIT(R) TEN-20 satisfying a
market pilot by the end of October 2010. The pilot will create
immediate marketing opportunities in selected markets while surveying
key factors influencing distribution and deployment decisions, such
as support for high-volume usage, multiple languages, and
'test-drives' by customers.

Biosign is set to deliver its products and services with Dell and
Dell Services on a global basis. Dell has been ranked first in
customer service and is arguably the largest healthcare IT company in
the world, making them a logical choice for our European product
launch.

Patrick Dressel, President of DynamiCARE stated: "DynamiCARE
focuses on providing innovative solutions to diabetics. The UFIT(R)
platform is the next evolution of testing and diagnostics for
personal medicine, promising a momentous impact on diabetes
monitoring in terms of cost, comfort, and convenience. Our sales
target reflects this promise."

UFIT(R) TEN-20 is an online medical device for self-monitoring of
blood pressure and blood glucose. The device takes the pulse at the
wrist through an inflatable cuff and gives blood pressure and blood
glucose measurement results. All measurements are indirect,
noninvasive, and passive. The results are stored on Biosign servers
along with the test sample.

Radu Leca, President of Biosign noted: "Europe represents one
third of the global market. It outpaces the world in providing the
best overall health care, with France, Austria, Switzerland, and
Germany as recognized global leaders. We are pleased with the
opportunity of using the cradle of modern medicine to launch our
radically unique product. In face of the magnitude of the task, we
will proceed prudently, harnessing DynamiCARE's presence in the
diabetes market and leveraging their channel partners to ensure a
successful launch."

About Biosign Technologies Inc.

Biosign Technologies Inc. (CNSX: BIO) provides biomedical
systems. Key applications include intelligent systems for noninvasive
monitoring of common health risks associated with blood pressure,
glucose, and medication. The core technology combines measurement,
analysis, and rapid knowledge formation to support health monitoring
across global markets. The UFIT(R) medical device technology powers
quality data collection and analytics for clinical diagnostics,
self-care, wellness, disease state evaluation & management, and
remote patient monitoring. For more information on Biosign please
visit http://www.biosign.com.

About DynamiCARE AG

DynamiCARE is a dynamic company with its head office in
Switzerland. The emphasis of the company is in the supply of products
to humans with diabetes. The credo of DynamiCARE is to assure that
people have access to affordable, high quality and reliable diabetes
care. Products include blood sugar measuring instruments, insulin pen
& needles, lancing devices, and innovative products for wound
management with nascent oxygen. For more information on DynamiCARE
please visit http://www.dynamicare.ch

About Dell Inc.

Dell Inc. listens to customers and delivers worldwide innovative
technology and business solutions they trust and value. Dell Services
develops and delivers a comprehensive suite of services and solutions
in applications, business process, consulting, infrastructure and
support to help customers succeed.

The CNSX has neither approved nor disapproved the contents of
this press release.

For further information: Radu Leca, President & CEO, Biosign
Technologies Inc., Phone: +1-(416)-218-9800 ext. 234, Email:
ceo@biosign.com

ots Originaltext: Biosign Technologies Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information: Radu Leca, President & CEO,
BiosignTechnologies Inc., Phone: +1-(416)-218-9800 ext. 234,
Email:ceo@biosign.com